Before the late 20th century, overweight and obesity were not considered population-wide health risks, but the advent of weight loss drugs in the 1990s accelerated hypermedicalization via BMI use.
AMA J Ethics. 2023;25(7):E550-558. doi:
10.1001/amajethics.2023.550.
More transparent pricing would allow patients and families to make better decisions, but there are limitations to how reliably it promotes efficiency and market discipline.
AMA J Ethics. 2022;24(11):E1069-1074. doi:
10.1001/amajethics.2022.1069.
Successful implementation of initiatives to improve screening and access to health-promotion activities at minority-serving religious institutions requires partnering with faith-based organizations, adapting interventions, and leveraging organizational infrastructure and social networks.
AMA J Ethics. 2018;20(7):E643-654. doi:
10.1001/amajethics.2018.643.